RU2733897C2 - Стабильные полипептиды, связывающиеся с с5 комплемента человека - Google Patents

Стабильные полипептиды, связывающиеся с с5 комплемента человека Download PDF

Info

Publication number
RU2733897C2
RU2733897C2 RU2016111115A RU2016111115A RU2733897C2 RU 2733897 C2 RU2733897 C2 RU 2733897C2 RU 2016111115 A RU2016111115 A RU 2016111115A RU 2016111115 A RU2016111115 A RU 2016111115A RU 2733897 C2 RU2733897 C2 RU 2733897C2
Authority
RU
Russia
Prior art keywords
leu
asp
glu
ala
ile
Prior art date
Application number
RU2016111115A
Other languages
English (en)
Russian (ru)
Other versions
RU2016111115A3 (enExample
RU2016111115A (ru
Inventor
Йоаким НИЛЬССОН
Эрик Нордлинг
Патрик СТРЕМБЕРГ
Original Assignee
Сведиш Орфан Биовитрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сведиш Орфан Биовитрум Аб (Пабл) filed Critical Сведиш Орфан Биовитрум Аб (Пабл)
Publication of RU2016111115A publication Critical patent/RU2016111115A/ru
Publication of RU2016111115A3 publication Critical patent/RU2016111115A3/ru
Application granted granted Critical
Publication of RU2733897C2 publication Critical patent/RU2733897C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
RU2016111115A 2013-08-28 2014-08-28 Стабильные полипептиды, связывающиеся с с5 комплемента человека RU2733897C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
SE1350986-4 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020128977A Division RU2020128977A (ru) 2013-08-28 2014-08-28 Стабильные полипептиды, связывающиеся с с5 комплемента человека

Publications (3)

Publication Number Publication Date
RU2016111115A RU2016111115A (ru) 2017-10-03
RU2016111115A3 RU2016111115A3 (enExample) 2018-04-25
RU2733897C2 true RU2733897C2 (ru) 2020-10-09

Family

ID=51539238

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016111115A RU2733897C2 (ru) 2013-08-28 2014-08-28 Стабильные полипептиды, связывающиеся с с5 комплемента человека
RU2020128977A RU2020128977A (ru) 2013-08-28 2014-08-28 Стабильные полипептиды, связывающиеся с с5 комплемента человека

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020128977A RU2020128977A (ru) 2013-08-28 2014-08-28 Стабильные полипептиды, связывающиеся с с5 комплемента человека

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3811961B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371B1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (2) RU2733897C2 (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6276202B2 (ja) 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー(ペーウーベーエル) ヒト補体c5に結合するポリペプチド
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
JP7138411B2 (ja) * 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
KR20250068795A (ko) 2017-07-11 2025-05-16 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
US20240124533A1 (en) * 2021-02-15 2024-04-18 Affibody Ab New her2-binding polypeptide
MX2024005285A (es) * 2021-11-01 2024-09-18 Ipc Res Llc Administracion de proteinas de union a c5.
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
US20050090448A1 (en) * 2003-09-10 2005-04-28 Baxter International Inc. Peptides that inhibit complement activation
WO2012004384A2 (en) * 2010-07-09 2012-01-12 Affibody Ab Polypeptides
RU2477137C2 (ru) * 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2424379C (en) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA3022097C (en) 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
ES2373832T3 (es) * 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PT2328616E (pt) 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
JP6276202B2 (ja) * 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー(ペーウーベーエル) ヒト補体c5に結合するポリペプチド
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
JP7138411B2 (ja) * 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
US20050090448A1 (en) * 2003-09-10 2005-04-28 Baxter International Inc. Peptides that inhibit complement activation
RU2477137C2 (ru) * 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
WO2012004384A2 (en) * 2010-07-09 2012-01-12 Affibody Ab Polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOKURIKI N. ET AL., Stability effects of mutations and protein evolvability, Curr. Opin. Struct. Biol., 2009, v.19, n.5, p.596-604. *

Also Published As

Publication number Publication date
RU2020128977A (ru) 2021-11-30
RU2016111115A3 (enExample) 2018-04-25
KR102446636B1 (ko) 2022-09-23
CA2926976C (en) 2023-11-28
AU2014314222A1 (en) 2016-04-21
CN105658228B (zh) 2020-02-07
RS61347B1 (sr) 2021-02-26
CY1123732T1 (el) 2021-10-29
MY173804A (en) 2020-02-24
WO2015028558A1 (en) 2015-03-05
EP3811961A1 (en) 2021-04-28
PL3038633T3 (pl) 2021-07-19
LT3038633T (lt) 2021-03-25
JP2016529270A (ja) 2016-09-23
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
CN105658228A (zh) 2016-06-08
BR122023020080A2 (pt) 2023-12-26
DK3038633T3 (da) 2021-01-11
HRP20210013T1 (hr) 2021-04-02
PH12016500371A1 (en) 2016-05-02
IL244218A0 (en) 2016-04-21
PH12016500371B1 (en) 2016-05-02
HUE052613T2 (hu) 2021-05-28
US9994626B2 (en) 2018-06-12
NZ718153A (en) 2022-05-27
MX382140B (es) 2025-03-13
SI3038633T1 (sl) 2021-05-31
US20160311870A1 (en) 2016-10-27
SA516370622B1 (ar) 2018-12-23
SMT202100006T1 (it) 2021-03-15
IL244218A (en) 2017-11-30
EP3038633A1 (en) 2016-07-06
JP2020172505A (ja) 2020-10-22
EP3038633B1 (en) 2020-10-14
PT3038633T (pt) 2021-01-14
JP6767865B2 (ja) 2020-10-14
EP3811961B1 (en) 2025-08-20
ES2842105T3 (es) 2021-07-12
RU2016111115A (ru) 2017-10-03
MX2016002397A (es) 2016-09-08
UA117933C2 (uk) 2018-10-25
SG11201602679VA (en) 2016-05-30
KR20160048121A (ko) 2016-05-03
HK1225656A1 (en) 2017-09-15
CA2926976A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
RU2733897C2 (ru) Стабильные полипептиды, связывающиеся с с5 комплемента человека
KR102365977B1 (ko) 단일 쇄 가변 단편 cd3 결합 단백질
Kipriyanov et al. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen
CN103459415B (zh) 设计的与血清白蛋白结合的重复蛋白
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
US20180194819A1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
CN109562167A (zh) 联合治疗
JP2023551481A (ja) 標的分子の選択的枯渇のための組成物及び方法
EP3258950A1 (en) Alzheimer abeta peptide binding polypeptide
CA3212924A1 (en) Multivalent proteins and screening methods
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
HK40050539A (en) Stable polypeptides binding to human complement c5
HK40050539B (en) Stable polypeptides binding to human complement c5
CN116262784A (zh) 增强FcRn亲和力的Fc变体
HK1225656B (en) Stable polypeptides binding to human complement c5
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
CA3268444A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
EP3325515B1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
HK40059771A (en) Designed repeat proteins binding to serum albumin